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A B S T R A C T
Objective: To develop and test an educational tool for older adults that increases risk perception about
benzodiazepines through knowledge acquisition and change in beliefs.
Methods: A written educational tool was mailed to 144 benzodiazepine consumers aged 65 years
recruited from community pharmacies. Knowledge and beliefs about inappropriate prescriptions were
queried prior to and 1-week after the intervention. Primary outcome was a change in risk perception.
Explanatory variables were a change in knowledge and beliefs about medications. Self-efﬁcacy for
tapering and intent to discuss discontinuation were also measured.
Results: Post-intervention, 65 (45.1%) participants perceived increased risk. Increased risk perceptions
were explained by better knowledge acquisition (mean change score 0.9, 95% CI (0.5, 1.3)), and a change
in beliefs (BMQ differential mean change score 5.03, 95% CI (6.4, 3.6)), suggesting elicitation of
cognitive dissonance. Self-efﬁcacy for tapering, (mean change score 31.2, 95% CI (17.9, 44.6)), and intent
to discuss discontinuation of benzodiazepine with a doctor (83.1% vs 44.3%, p < 0.001) were higher
among participants who perceived increased risk.
Conclusion: Risk perception surrounding inappropriate prescriptions can be altered through direct
delivery of an educational tool to aging consumers.
Practice implications: Patients should be targeted directly with information to catalyze discontinuation
of inappropriate prescriptions.
 2013 Elsevier Ireland Ltd. 
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Medication safety in the elderly population represents a unique
challenge. Older adults are at increased risk of drug side effects,
drug-drug interactions and adverse events due to age-related
changes and associated disease [1,2]. The 2012 updated Beers
Criteria for Potentially Inappropriate Medication Use in Older
Adults lists all drugs-to-avoid in the elderly to reduce the risk of
drug-related adverse events [3,4]. All benzodiazepine sedative-
hypnotic drugs used for the treatment of anxiety and insomnia
feature on this list due to an excessive risk of delirium, falls,
fractures and motor vehicle accident [5].
With every update to the Beers criteria, signiﬁcant efforts are
made to inform and educate relevant parties to try and implement* Corresponding author at: Institut Universitaire de Ge´riatrie de Montre´al,
Faculties of Pharmacy and Medicine, Universite´ de Montreal, 4545 Queen Mary
Road Montreal, QC H3W 1W5, Canada. Tel.: +1 514 340 3540x2526;
fax: +1 514 340 2117.
E-mail address: cara.tannenbaum@umontreal.ca (C. Tannenbaum).
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Open access under CC BY-NC-ND license.safer prescribing practices. We sought to develop an educational
intervention to inform consumers directly about the risk of
benzodiazepine drugs. We chose benzodiazepine drugs because
qualitative research suggests that chronic users develop a
psychological dependence to benzodiazepines, attributing them
qualities that extend beyond their ordinary capacity [6]. Most
consumers deny or minimize side effects while expressing subtle
reluctance to outright refusal for being left suffering without these
medications [6]. For these reasons physicians often express
reticence for insisting on benzodiazepine discontinuation for fear
of upsetting the doctor-patient relationship or because they
believe that the patient tolerates the medication with minimal side
effects [7].
The objective of this study was to develop and test an
educational tool targeted directly to older consumers on the risks
associated with benzodiazepine use in the geriatric population. By
applying constructivist learning theory to the development of the
educational intervention, we aimed to evaluate the potential of
this tool for increasing the patient’s risk perception by eliciting
cognitive dissonance through knowledge acquisition and belief
alteration. We hypothesized that improvements in patient
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greater motivation for initiating discussions about drug discontin-
uation with a doctor or pharmacist and greater self-efﬁcacy for
tapering benzodiazepine use.
2. Methods
A quasi-experimental study was conducted among a cohort of
chronic benzodiazepine users aged 65 years and older in Montreal,
Canada. Participants were randomized to immediately receive an
educational intervention to reduce inappropriate prescriptions or
to a six-month wait-list group. The current analysis presents
interim results on short-term changes in risk perceptions about
benzodiazepines due to the intervention. The study was approved
by the Institut Universitaire de Ge´riatrie de Montre´al Ethics
Committee in Montreal, Quebec, Canada.
2.1. Participants
The study population included community-dwelling men and
women aged 65 years and older, consuming at least ﬁve
prescription medications including a benzodiazepine dispensed
for at least three consecutive months. Exclusion criteria were a
diagnosis of severe mental illness or dementia ascertained by the
presence of an active prescription for any antipsychotic medication
and/or a cholinesterase inhibitor or memantine. Participants
unable to communicate in French and/or English or showing
evidence of signiﬁcant cognitive impairment (score under 21 [8] on
the MOCA (Montreal Cognitive Assessment)) were also excluded.
2.1.1. Recruitment
Participants were recruited from community pharmacies in the
greater Montreal area. Pharmacists identiﬁed eligible patients
from their databases and invited them to enroll in the study
through personalized mailed invitations, referring them to the
study coordinator. A telephone follow up from the pharmacist (or
delegate) aimed to ascertain interest in the study from eligible
participants who had not spontaneously contacted the coordina-
tor. An appointment was made with the study coordinator at
participant’s residence for those who provided permission to be
contacted for the study. Signed consent was obtained from
individuals who met study criteria after baseline cognitive and
health status screening.
2.2. The educational intervention
2.2.1. Theory and development of the intervention
Social cognitive theory, which consists of health promotion
through social cognitive means, guided the development of the
intervention [9]. The speciﬁc learning model that was applied was
constructivist learning. Constructivist learning theory aims to
promote active learning through creation of knowledge that seeks
to make sense out of the material presented. The goal of this
approach is to create an environment where the learner can
interact with academic material, fostering their own selecting,
organizing and information integrating processes [10]. Such
theories have already proven successful in other health promotion
interventions such as in educational materials for smoking
cessation [11].
A critical component of constructivist learning theory is
elicitation of cognitive dissonance [12]. Cognitive dissonance
occurs when a person’s preconceived notions about the self and the
world clash with new knowledge acquisition; the discrepancy that
is evoked results in a state of tension known as cognitive
dissonance [12]. Our educational intervention for reducing
benzodiazepine use was developed to create cognitive dissonanceby soliciting an aversive motivational state in recipients by
confronting two inconsistent cognitions on benzodiazepine use.
The theory holds that as the experience of dissonance is
unpleasant, the individual will be motivated to remove the
pressure caused by this conﬂict by altering one of these
perceptions to achieve consonance [12]. For instance, if an
individual previously believed that benzodiazepines were safe,
the threatening content of the tool challenges this belief by
providing information that benzodiazepines incur several harmful
risks, thus putting into question whether consumption should be
continued [13,14] We also incorporated social comparison theory
into the content of the intervention to reassure participants about
their newfound uncertainty regarding benzodiazepine use. Social
comparison states that: ‘‘people evaluate their opinions and
abilities by comparison respectively with the opinions and abilities
of others’’[15]. It thus consists of comparing oneself with others in
order to evaluate or to enhance some aspects of the self [16]. Here,
the evaluation of the ability or inability to do a speciﬁc action relies
on the success of a proxy performer. The efﬁcacy of this theory
depends on whether the comparer assimilates or contrasts him/
herself to others [17]. Comparability with a peer champion’s
narrative and previous agreement with the peer’s views are
important factors for the comparison to work [16]. A self-
assessment component was also introduced, which aimed to
promote insight about potential misinformation or beliefs held
about benzodiazepine use by providing feedback on incorrect
assumptions [18,19].
Textual content of the intervention was based on a systematic
review of the evidence as well as guidelines concerning the use of
benzodiazepines in the elderly. A geriatrician and graduate student
drafted the initial content of the tool, which was then validated by
a panel of colleagues with expertise in geriatric pharmacy and
reviewed by a health librarian to ensure that the wording met
standards for patient literacy at the Grade 6 level. The tool was
developed in English, and backward and forward translated into
French.
2.2.2. Components of the intervention
The cover page of the brochure states ‘‘You May Be At Risk’’ with
a picture of a pillbox with several medications in it, followed by
‘‘You are currently taking (name of the patient’s benzodiazepine)’’.
The ﬁrst page of the intervention is entitled ‘‘Test Your Knowledge’’
and consists of four true or false questions on the use of the
benzodiazepines. The second page lists the correct answers.
Elements of constructivist learning theory are incorporated into
the answers to create cognitive dissonance and challenge the
patient’s beliefs for each incorrect answer. The third page
incorporates self-assessment and education about potential
inappropriate use, side effects, drug-drug interactions and
information about physiologic changes that occur with age that
affect drug metabolism. The fourth and ﬁfth pages present
evidence-based risks associated with benzodiazepine use in the
elderly and suggestions for equally or more effective therapeutic
substitutes. The sixth page describes a case scenario highlighting
one woman’s success at weaning herself off benzodiazepines. The
last page outlines a simple 21-week tapering program. The reader
is encouraged on four occasions and is warned in large, red
lettering to ‘‘Please Consult your Doctor or Pharmacist Before
Stopping Any Medication.’’
2.2.3. Acceptability of the intervention
The tool was ﬁeld-tested with a convenience sample of older
adults to determine the readability and comprehension of the
information. Six focus-groups (n = 60 adults) were conducted.
Based on the focus group discussions, the wording, ordering of the
material and visual presentation of the intervention was changed
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educational intervention consisted of a seven-page letter-size
paper brochure written in 14-point font. The educational tool was
mailed to the study participants within six months of the initial
assessment.
2.3. Study outcomes
2.3.1. Primary outcomes
The primary outcome was a self-reported change in perception
of risk associated with benzodiazepine use one week post-
intervention. Participants were asked whether they perceived
the same, increased, or no risk from consumption of their
benzodiazepine following the intervention. A common idea in
models of risk perception is that risk is perceived from two
dimensions: the ﬁrst being knowledge about the risk, and the
second, beliefs about that risk [20]. To explain changes in
perception of risk we therefore measured changes in knowledge
and beliefs about medications as a mechanism through which
cognitive dissonance could occur.
Change in knowledge was measured by comparing the pre-
intervention and post-intervention answers from the four-item
true or false questions listed in the ‘‘Test Your Knowledge’’ section
of the questionnaire. The ﬁrst statement on the safety of long-term
benzodiazepine was ‘‘(Example: Ativan1). . .is a mild tranquilizer
that is safe when taken for long periods of time’’. The second
statement focused on side effects and was worded, ‘‘The dose of
Ativan1 that I am taking causes no side effects.’’ The third
statement on withdrawal was phrased, ‘‘Without Ativan1 I will be
unable to sleep or will experience unwanted anxiety,’’ and the
fourth statement on alternative treatment options reads: ‘‘Ati-
van1 is the best available option to treat my symptoms’’.
Change in beliefs was measured by comparing the pre- and
post-intervention total scores on the speciﬁc section of the beliefs
about medicines questionnaire (BMQ-Speciﬁc) adapted for ben-
zodiazepines [21,22]. The rationale for choosing the BMQ-Speciﬁc
instrument to measure beliefs relates to its ability to isolate and
score participants’ beliefs (second dimension of risk perception)
about a speciﬁc medication, both in terms of the necessity of taking
their prescription (Speciﬁc-Necessity) and the dangers of this same
prescription, such as long term toxicity, side-effects and depen-
dence (Speciﬁc-Concerns). The BMQ-speciﬁc consists of two ﬁve-
items factors belonging to each sub-score. Participants indicate
their degree of agreement with each statement on a 5 point Likert
scale (where 1 = strongly disagree through 5 = strongly agree).
Scores are then summed into their respective sub-category (5–25
scale) with higher scores indicating stronger beliefs. A necessity-
concerns differential can also be calculated by subtracting the
concern sub-score from the necessity sub-score. This differential
can be thought of as the cost beneﬁt analysis for each patient,
where costs (concerns) are weighed against perceived beneﬁts
(necessity beliefs) [21,22]. A negative change in BMQ-differential
score thus indicates a greater perception of risk.
2.3.2. Secondary outcomes
Two secondary outcomes were selected to measure anticipated
behaviors potentially resulting from a change in risk perception:
self-efﬁcacy for tapering benzodiazepines and the intent to discuss
benzodiazepine discontinuation with a doctor or pharmacist. The
behavior motivation hypothesis was used to understand the
drivers and consequences of risk perception. This hypothesis
describes the determinants of risk perception and their effects on
behavior change, and is endorsed by most models of health
behavior [23]. Perception of risk has been shown to be positively
related to preventive health behavior when expectations of
success in dealing with the risk are acceptable, and whenrecommendations for preventive behavior are presented as
effective [24]. Self-efﬁcacy for tapering benzodiazepines was
measured pre- and post-intervention on the Medication Reduction
Self-efﬁcacy scale, which allows the respondent to rate on a scale of
0 to 100 their degree of conﬁdence for tapering and discontinuing
benzodiazepines [25].
In order to measure anticipated behavior as a function of the
participant’s willingness to empower themselves in health-related
decisions following the intervention, participants were asked to
indicate (yes/no) post intervention: if they had spoken to friends
and family about the intervention, and if they had spoken to or
intended to discuss medication discontinuation with their doctor
and/or pharmacist. These intentions were considered as a
preliminary measure of preventive health behavior. Finally, initial
reaction to the questionnaire and whether they had read it more
than once was also collected.
Outcomes were measured at baseline and one week following
receipt of the intervention. At baseline, questionnaires were
completed at the participants’ homes during an interview with the
research coordinator. Follow up was by telephone interview with
the same coordinator. Self-reported socio-demographic variables,
health status variables and prescription details were collected at
baseline.
2.4. Statistical analysis
Participant characteristics were summarized using means with
standard deviations for continuous data and percentages for
categorical data. The number of participants reporting increased
risk perceptions one week after the intervention was reported as a
proportion of all participants. To examine potential differences in
the baseline characteristics of participants who perceived in-
creased risk versus those who did not, group comparisons were
conducted. There were few missing baseline data (n = 0–5 per
variable), which were replaced by the mean group value.
To determine whether a change in knowledge or beliefs
explained changes in risk perception as a result of receiving the
educational intervention, changes in knowledge and beliefs from
pre- to post-intervention were computed for each individual, as
well as within and between groups of individuals who reported
increased risk perceptions versus those who did not. Correct
knowledge pre- and post-intervention was reported as the
proportion of individuals endorsing the correct answer for each
question. A sub-analysis among participants with potential for
change, denoted by CAIA, or Change in the Answer from an
Incorrect Answer, was also conducted to determine change in
knowledge among participants who initially answered a question
incorrectly, but subsequently changed to the correct answer at 1-
week follow-up. Participants with correct answers at both time-
points were thus excluded from the CAIA measure, as there was no
potential for cognitive dissonance. An overall score for knowledge
was computed as the sum of correct answers (0–4 range). A change
in belief was measured by comparing the BMQ-speciﬁc-necessity
score, speciﬁc-concern score and necessity-concern differentials
both within and between the increased risk and no increased risk
group. Participants who had evidence of both a change in
knowledge and a change in beliefs were denoted as having
experienced cognitive dissonance.
Self-efﬁcacy scores for discontinuing benzodiazepines were
compared both within and between RISK groups from baseline to
post intervention, as were responses to the query about self-
efﬁcacy for tapering benzodiazepines. Participants with missing
data for any of the BMQ-speciﬁc variables (n = 3) or the self-
efﬁcacy variables (n = 7–8) were withdrawn from these analyses.
In order to determine the increased likelihood of anticipated
preventive behaviors according to risk perception, the odds of
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univariate logistic regression. Missing data were replaced by a
negative answer for the latter analyses,
A chi-square test was used when comparing groups while
McNemar’s test was used to examine changes within groups from
baseline to post-intervention for categorical variables. Independent
t-tests were used to compare groups while paired t-tests were used
to examine changes within groups from baseline to post-interven-
tion for continuous variables. The statistical signiﬁcance for all
analyses was set at p < 0.05 (two-sided). SPSS Version 20.0 (SPSS Inc.
Chicago, IL, USA) was used for all analyses.
3. Results
3.1. Recruitment
Participants were recruited from 12 pharmacies. The response
rate to the mailed invitation to enroll in the study among eligible
participants identiﬁed by their pharmacists was 15%. A total of 144
participants who received the educational intervention are
included in this analysis.
3.2. Baseline characteristics
Table 1 shows demographic, general health status and
prescription-related characteristics of the entire cohort at baseline.
Participants were mostly female (73%), had an average age of 75,
and the majority (83%) had no formal college or university
education. Half of all participants had previously attempted
benzodiazepine discontinuation, 25% of whom had successfully
weaned off the drug at some point.
3.3. Change in risk perceptions
Post-intervention, 45.1% (n = 65) of participants reported
increased perceived risk from consumption of benzodiazepines.
There were no statistical differences in baseline characteristics
between individuals perceiving an increased risk (RISK) and those
with no perceptions of increased risk (NO RISK), except for a trend
showing a shorter duration of benzodiazepine use among the RISK
group (p = 0.08) (Table 1).
3.4. Change in knowledge
Knowledge about benzodiazepines was similar between
groups at baseline. Changes in knowledge both within andTable 1
Descriptive demographic and health status characteristics at baseline. Values are mean
Characteristics All (N = 144) 
Female, n (%) 105 (73%) 
Age (years), mean (SD) 74.9 (6.5) 
College or University education, n (%) 25 (17%) 
Living alone, n (%) 69 (48%) 
MOCAb, mean (SD) 25.4 (2.4) 
General health status (fair to bad), n (%) 43 (30%) 
Comorbidities, mean (SD) 7.0 (2.5) 
Indication for taking Benzodiazepines, n (%)
Insomnia 94 (65%) 
Anxiety 64 (44%) 
Duration of benzodiazepine use (years), mean (SD) 10.5 (8.2) 
Previous attempts at cessation, n (%) 80 (56%) 
Successful attempts, n (%) 20 (25%) 
Independent sample t-test for continuous variables, chi square for categorical variable
* Level of signiﬁcance, p < 0.05 [28].
a RISK: Perceived an increased risk vs NO RISK: perceived no risk or same risk as pr
b MOCA: The Montreal Cognitive Assessment (scale 0–30)between risk groups are described in Table 2. Eighty percent
(52/65) of participants in the RISK group changed an answer
from incorrect to correct on at least one knowledge question
from pre- to post-intervention compared to only 41% (33/79) in
the NO RISK group. The RISK group demonstrated a signiﬁcantly
higher proportion of correct answers post-intervention on the
safety, side effects and alternatives questions compared to the
NO RISK group (p < 0.001). Only participants in the RISK group
who had the potential for knowledge acquisition showed a
statistically signiﬁcant increase on the overall knowledge score
(mean change score 1.77 SD (1.3)). The change in overall score
was signiﬁcantly greater among these individuals in the RISK
group post-intervention compared to the NO RISK group (mean
change score 0.91 95% CI (0.5, 1.3)).
3.5. Changes in beliefs
Beliefs about benzodiazepines were similar between groups at
baseline. Tables 3a and 3b show changes in beliefs about the
necessity, perceived negative consequences, and risk-beneﬁt ratio
of benzodiazepine use. Eighty-three percent (54/65) of partici-
pants in the RISK group had an improved BMQ-differential score
(negative change) from baseline to follow-up, indicating in-
creased risk perception, compared to 27% (31/79) of participants
in the NO RISK group. The RISK group showed statistically
signiﬁcant group differences across all three of these BMQ
outcomes (p < 0.001) while no signiﬁcant group changes were
detected in the NO RISK group. Post-intervention, the RISK group
reported signiﬁcantly lower scores on the necessity subscale
(mean change score 1.31, 95% CI (2.3, 0.4)), signiﬁcantly
higher scores on the concerns subscale (mean change score 3.72,
95% CI (2.9, 4.5)) and a statistically greater necessity-concerns
differential (mean change score 5.03, 95% CI (6.4, 3.6)),
compared to the NO RISK group.
3.6. Frequency of cognitive dissonance
According to an operational deﬁnition of cognitive dissonance
predicated upon a change in knowledge and a change in beliefs
about benzodiazepine consumption due to receipt of the
intervention, 44/65 (68%) of participants in the RISK group and
19/79 (24%) of participants in the NO RISK group experienced
cognitive dissonance. The experience of cognitive dissonance was
associated with a six-fold higher likelihood of patients reporting
increased risk perception about their benzodiazepine prescription
(OR = 6.61 95%CI (3.2, 13.8))., standard deviation (SD) or number (%).
RISKa (N = 65) NO RISKa (N = 79) p-Value
47 (72%) 58 (73%) 0.88
75.3 (6.1) 74.6 (6.8) 0.52
11 (17%) 14 (18%) 0.90
29 (45%) 40 (51%) 0.47
25.4 (2.4) 25.4 (2.5) 0.94
19 (29%) 24 (30%) 0.88
6.8 (2.3) 7.1 (2.6) 0.62
42 (65%) 52 (66%) 0.88
27 (42%) 37 (47%) 0.52
9.2 (7.8) 11.6 (8.4) 0.08
32 (49%) 48 (61%) 0.24
5 (16%) 15 (31%) 0.11
s.
e-intervention.
Table 2
Effect of the educational tool on knowledge. Values are number (%), mean or standard deviation (SD).
Variables Within groups at one week Between groups at week 1
Questions Group Baseline p-Value
(between
groups)
Post-
intervention
CAIAb, n
(%)
p-Value
(CAIAb)
Difference
(%)
p-Value Difference
in CAIAb (%)
p-Value
(CAIAb)
1 – safety, n
(% with correct answer)
RISKa (n = 65) 23 (35.4%) 0.75 56 (86.2%)* 33/42 (78.6%)* <0.001 34.3* <0.001 39.9* <0.001
NO RISKa (n = 79) 26 (32.9%) 41 (51.9%)* 24/62 (38.7%)* 0.014
2 – side-effects, n
(% with correct answer)
RISKa (n = 65) 4 (6.2%) 0.51c 28 (43.1%)* 26/63 (41.3%)* <0.001 30.4* <0.001 30.5* <0.001
NO RISKa (n = 79) 3 (3.8%) 10 (12.7%)* 8/77 (10.4%)* 0.039
3 – withdrawal, n
(% with correct answer)
RISKa (n = 65) 13 (20.0%) 0.69 32 (49.2%)* 21/55 (38.2%)* <0.001 11.6 0.13 11.7 0.17
NO RISKa (n = 79) 18 (22.8%) 29 (36.7%)* 18/68 (26.5%)* 0.043
4 – alternatives, n
(% with correct answer)
RISKa (n = 65) 7 (10.8%) 0.17 41 (63.1%)* 35/60 (58.3%)* <0.001 29.8* <0.001 32.6* <0.001
NO RISKa(n = 79) 15 (19.0%) 27 (34.2%)* 18/70 (25.7%)* 0.023
Test score Group Baseline p-Value
(between
groups)
Post-
intervention
CAIAb,
Mean (SD)
p-Value
(CAIAb)
Difference
(95% CI)
p-Value CAIAb
(95% CI)
p-Value
(CAIAb)
Overall (/4),
mean (SD)
RISKa(n = 65) 0.72 (0.9) 0.69 2.42 (1.3) 1.77 (.1.3)* <0.001 1.06 (.6, 1.5)* <0.001 0.91 (.5, 1.3)* <0.001
NO RISKa (n = 79) 0.79 (0.9) 1.35 (1.3) 0.86 (1.10) 0.682
Within groups: Paired t-test for continuous Variables, McNemar’s test for categorical variables. Between groups: Independent sample t-test for continuous variables, chi
square for categorical variables.
a RISK: perceived an increased risk vs NO RISK: perceived no risk or same as pre-intervention.
b CAIA: change among those with an incorrect answer (excludes participants with correct answers at both time-points).
c Wilcoxon non-parametric test.
* Level of signiﬁcance, p < 0.05 [28].
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The RISK group reported signiﬁcantly greater improvements in
self-efﬁcacy for discontinuing benzodiazepines following the
intervention (mean change score 31.24 95% CI (17.9, 44.6))
compared to the NO RISK group. The added beneﬁt of the tapering
protocol on self-efﬁcacy scores for discontinuing benzodiazepines
within the RISK group was an extra 6.05 points on the self-efﬁcacy
scale, 95% CI (3.0, 9.1). No statistically signiﬁcant differences in
self-efﬁcacy were found in the NO RISK group.
3.8. Change in health behaviors aimed at discontinuing
benzodiazepine use
Fig. 1 shows correlates and anticipated behaviors associated
with an increased risk perception post-intervention. The RISK
group reported a signiﬁcantly higher likelihood of reading the tool
more than once (OR = 8.34 95% CI (3.9, 17.9)), intention to discuss
the intervention with family and friends (OR = 2.65 95% CI (1.3,
5.5)), and intention to discuss discontinuation with a physician
(OR = 6.17 95% CI (2.8, 13.5)), or pharmacist (OR = 6.29 95% CI (2.8,
14.3)), compared to the NO RISK group.
4. Discussion and conclusion
Findings from this study indicate that a personalized patient-
targeted benzodiazepine educational intervention delivered di-
rectly to the individual consumer via written material wasTable 3a
Change in beliefs associated with risk perception post-intervention. Values are mean o
Variables Within groups at one week 
Group Baseline Post-interventi
Belief about necessity
of the drugb, Mean (SD)
RISKa 14.22 (3.3) 12.60 (2.4) 
NO RISKa 13.97 (3.7) 13.91 (3.3) 
Belief about side-effects
of the drugb, Mean (SD)
RISKa 13.40 (2.3) 16.14 (2.5) 
NO RISKa 12.71 (2.1) 12.42 (2.3) 
Necessity Concernc
differential, Mean (SD)
RISKa 0.83 (4.3) 3.54 (3.8) 
NO RISKa 1.27 (4.6) 1.49 (4.4) 
Self-efﬁcacy for discontinuation
of drugd, Mean (SD)
RISKa 32.42 (33.4) 68.71 (36.6) 
NO RISKa 31.9 (35.1) 37.47 (42.4) effective in changing medication risk perceptions in 45% of older
chronic users. Heightened risk perception was explained by
signiﬁcant changes in knowledge and beliefs about benzodiaze-
pines due to receipt of the tool. Our study suggests that
participants in whom the intervention elicited changes in
knowledge and beliefs may have experienced cognitive dissonance
as the mechanism underlying increased risk perception. Partici-
pants with increased risk perception reported greater self-efﬁcacy
for tapering benzodiazepines, and marked intent to engage in
preventive health behaviors by discussing medication safety with a
health professional.
The participants in this study are representative of other older
chronic benzodiazepine users reported in previous studies, with a
mean age of 77 years and a 10-year average duration of
benzodiazepine use [6,9,26]. Neither age nor duration of use were
signiﬁcant predictors of the ability to perceive increased risk,
suggesting that our intervention is effective in a wide range of
individuals regardless of entrenched habits or beliefs. To the best of
our knowledge, this study is the ﬁrst to demonstrate a positive effect
of targeting older adults directly about medication appropriateness,
thereby bypassing health professionals and engaging patients as
drivers of change to catalyze physicians and/or pharmacists in a
collaborative effort to reduce medication-related risk.
4.1.1. Mechanisms underlying the change in risk perception
The educational intervention developed in the current study
aimed to change risk perception by creating cognitive dissonancer standard deviation (SD).
Between groups at week 1
on Difference (95% CI) p-Value Difference (95% CI) p-Value
1.62 (2.5, 0.8) * <0.001 1.31 (2.3, 0.4)* 0.007
0.06 (0.9, 0.8) 0.883
2.75 (2.0, 3.5) * <0.001 3.72 (2.9, 4.5)* <0.001
0.28 (0.8, 0.3) 0.296
4.37 (5.6, 3.1)* <0.001 5.03 (6.4, 3.6)* <0.001
0.22 (.9, 1.3) 0.697
36.29 (24.8, 47.8)* <0.001 31.24 (17.9, 44.6)* <0.001
5.56 (4.5, 15.6) 0.276
Table 3b
Added impact of tapering tool on self-efﬁcacy for discontinuation post-intervention.
Variables Group On their own With Tapering
tool
Added value
of tool (95% CI)
p-Value Difference (95% CI) p-Value
Self-efﬁcacy for discontinuation
of drugd, mean (SD)
RISKa 68.71 (36.6) 74.80 (32.3) 6.05 (3.0, 9.1)* <0.001 32.66 (20.1, 45.2)* <0.001
NO RISKa 40.68 (42.4) 42.09 (41.6) 1.42 (1.7, 4.5) 0.368
Within groups: paired t-test, between groups: independent sample t-test.
a RISK: perceived an increased risk vs NO RISK: perceived no risk or same as pre-intervention.
b Speciﬁc-necessity and concern scales range from 5 to 25, higher scores indicating more agreement with the concept.
c ‘‘Beneﬁt-risk ratio’’, necessity – concern scale, ranges from 20 to 20.
d Scaled from 0 to 100.
* Level of signiﬁcance, p < 0.05 [28].
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comparison. We hypothesized that a change in knowledge and
beliefs would create cognitive dissonance, thus leading to a change
in risk perception. Unfortunately our study was not designed to
ascertain cognitive dissonance directly. By operationalizing
cognitive dissonance as a change in both knowledge and beliefs,
we were able to show that individuals who experienced cognitive
dissonance were six times more likely to report increased risk, thus
supporting the application of constructivist learning theory.
Interestingly, the intervention was only effective in changing risk
perceptions in 45% of participants. This may be explained by the
fact that many benzodiazepine users are psychologically depen-
dent on their medication. This psychological dependence likely
creates compelling opposition to new learning and denial of risk,
possibly explaining the lack of signiﬁcance across all components
of the tool for the 55% of participants who reported no increase in
risk perception. Our ﬁndings are consistent with another study on
medication discontinuation where the majority of participants
tended to reject the ﬁrst suggestion of discontinuation [6], as well
as with studies on breast cancer risk by Alexander et al. where only
50% of participants changed risk perceptions when presented with
an educational intervention [27].
Baseline knowledge was similar across all participants, with the
greatest knowledge change occurring in participants who per-
ceived increased risk. Participants who correctly answered the
knowledge questions post-intervention were eight times more
likely to reread the tool (OR = 8.34, 95% CI (3.9, 17.9)) than those
who perceived no increased risk suggesting that rereading the
intervention may be associated with better learning.
4.1.2. Preventive health behavior
Our results also showed a signiﬁcant difference between
groups on self-reported intent to discuss medicationFig. 1. Correlates and anticipated behaviors associated with risk perception. y RISK:
perceived an increased risk vs NO RISK: perceived no risk or same as pre-
intervention. *p < 0.01 for difference between groups using chi-square.discontinuation with a family member, pharmacist or physician.
These measures signify readiness to engage in preventive health
behaviors. Whether or not these intentions translate into action
remains to be determined.
4.1.3. Strengths and limitations
The major strength of this study was systematic measure-
ment of knowledge, beliefs and risk perceptions. Missing data
was imputed to reﬂect a worst-case scenario, and at best
underestimated the impact of the intervention. Few validated
instruments exist to reliably measure benzodiazepine-related
knowledge, beliefs and behaviors. Although the BMQ-Speciﬁc
questionnaire has been previously tested, the benzodiazepine-
related knowledge questions were not. Similarly, risk perception
was measured with a single self-reported item and not a full
instrument, and the elicitation of cognitive dissonance was
assumed rather than measured directly. Finally, this study was
conducted in community pharmacies and thus is not generaliz-
able to frailer patients living in health care facilities or long-
term care.
4.2. Conclusion
In conclusion, a home-based educational program consisting
of a document mailed to participants demonstrated
signiﬁcant effects on medication knowledge, beliefs and risk
perception in a cohort of older benzodiazepine users. By
changing knowledge and increasing perceived risk, consumer-
targeted drug information elicited a desire among many older
adults to discuss medication safety with their health care
providers. The results of an ongoing randomized trial will
demonstrate whether these changes wrought by the educational
intervention are sufﬁcient to result in discontinuation of
inappropriate prescriptions.
4.3. Practice implications
The aging consumer may be an under-utilized catalyst
of change for reducing potentially inappropriate prescriptions.
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